Phase II, multicentre study evaluating cisplatin (P), epirubicin (E) and vinorelbine (V) as first line chemotherapy (CHT) in advanced breast cancer (ABC): A new promise

MLA

Cazzaniga, Me, et al. “Phase II, Multicentre Study Evaluating Cisplatin (P), Epirubicin (E) and Vinorelbine (V) as First Line Chemotherapy (CHT) in Advanced Breast Cancer (ABC): A New Promise.” Journal of Clinical Oncology, vol. 22, July 2004, p. 761. EBSCOhost, https://doi.org/10.1200/jco.2004.22.90140.761.

APA

Cazzaniga, M., Demontis, C., Capra, D., Carlo Alberto TONDINI, Massidda, B., Ardizzoia, A., Zaniboni, A., Labianca, R., Ionta, M., & Barni, S. (2004). Phase II, multicentre study evaluating cisplatin (P), epirubicin (E) and vinorelbine (V) as first line chemotherapy (CHT) in advanced breast cancer (ABC): A new promise. Journal of Clinical Oncology, 22, 761. https://doi.org/10.1200/jco.2004.22.90140.761

Chicago

Cazzaniga, Me, C. Demontis, D. Capra, Carlo Alberto TONDINI, B. Massidda, A. Ardizzoia, A. Zaniboni, R. Labianca, Mt Ionta, and S. Barni. 2004. “Phase II, Multicentre Study Evaluating Cisplatin (P), Epirubicin (E) and Vinorelbine (V) as First Line Chemotherapy (CHT) in Advanced Breast Cancer (ABC): A New Promise.” Journal of Clinical Oncology 22 (July): 761. doi:10.1200/jco.2004.22.90140.761.